Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
PFE's Cash-to-Debt is ranked lower than
76% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. PFE: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.78 Max: N/A
Current: 0.33
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
84% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Interest Coverage 11.61
PFE's Interest Coverage is ranked lower than
71% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. PFE: 11.61 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.61
5.27
18.94
Piotroski F-Score: 6
Altman Z-Score: 2.31
Beneish M-Score: -2.58
WACC vs ROIC
7.50%
13.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 26.25
PFE's Operating Margin % is ranked higher than
89% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. PFE: 26.25 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 26.25
14.53
29.44
Net Margin % 13.92
PFE's Net Margin % is ranked higher than
75% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. PFE: 13.92 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 13.92
12.67
42.65
ROE % 11.92
PFE's ROE % is ranked higher than
67% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. PFE: 11.92 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 11.92
9.29
27.93
ROA % 4.29
PFE's ROA % is ranked higher than
54% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. PFE: 4.29 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.3
Current: 4.29
4.05
12.3
ROC (Joel Greenblatt) % 59.08
PFE's ROC (Joel Greenblatt) % is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.97 vs. PFE: 59.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 59.08
40.74
82.01
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
52% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 7.3 Max: 19.2
Current: 4.7
-2.5
19.2
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 8 Max: 36.8
Current: -10.1
-10.1
36.8
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 5.6 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 4 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:NVS, NYSE:MRK, OTCPK:RHHBY, NYSE:SNY, OTCPK:BAYRY, NYSE:ABBV, OTCPK:GLAXF, NYSE:LLY, NYSE:BMY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a research-based biopharmaceutical company. The Company's portfolio includes medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing over 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!
Nasdaq Reports Another New High Dow Jones and S&P 500 report losses for the day
U.S. market indexes were mixed on Tuesday with the Nasdaq reporting another new high. Read more...
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that offer returns of 21% or more!
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more!
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

Ratios

vs
industry
vs
history
PE Ratio 28.62
PFE's PE Ratio is ranked lower than
51% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.12 vs. PFE: 28.62 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.52 Max: 34.77
Current: 28.62
7.68
34.77
Forward PE Ratio 13.28
PFE's Forward PE Ratio is ranked higher than
75% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.73 vs. PFE: 13.28 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.38
PFE's PE Ratio without NRI is ranked higher than
50% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.32 vs. PFE: 28.38 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.34 Max: 34.43
Current: 28.38
9.83
34.43
Price-to-Owner-Earnings 18.08
PFE's Price-to-Owner-Earnings is ranked higher than
75% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.72 vs. PFE: 18.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.92 Max: 36.49
Current: 18.08
5.44
36.49
PB Ratio 3.47
PFE's PB Ratio is ranked lower than
58% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. PFE: 3.47 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.44 Max: 3.72
Current: 3.47
1.32
3.72
PS Ratio 3.97
PFE's PS Ratio is ranked lower than
59% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. PFE: 3.97 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.63 Max: 4.74
Current: 3.97
1.72
4.74
Price-to-Free-Cash-Flow 15.34
PFE's Price-to-Free-Cash-Flow is ranked higher than
72% of the 210 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.65 vs. PFE: 15.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.05 Max: 18.91
Current: 15.34
5.02
18.91
Price-to-Operating-Cash-Flow 13.32
PFE's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 284 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.79 vs. PFE: 13.32 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.73 Max: 15.89
Current: 13.32
4.55
15.89
EV-to-EBIT 23.47
PFE's EV-to-EBIT is ranked lower than
56% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. PFE: 23.47 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.5 Max: 28.8
Current: 23.47
6.7
28.8
EV-to-EBITDA 14.73
PFE's EV-to-EBITDA is ranked higher than
60% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.60 vs. PFE: 14.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 14.73
4.9
17.3
Shiller PE Ratio 21.50
PFE's Shiller PE Ratio is ranked higher than
79% of the 196 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.28 vs. PFE: 21.50 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.12  Med: 16.74 Max: 25.32
Current: 21.5
9.12
25.32
Current Ratio 1.44
PFE's Current Ratio is ranked lower than
75% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. PFE: 1.44 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.53 Max: 3.18
Current: 1.44
0.98
3.18
Quick Ratio 1.14
PFE's Quick Ratio is ranked lower than
71% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. PFE: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.23 Max: 2.86
Current: 1.14
0.74
2.86
Days Inventory 225.46
PFE's Days Inventory is ranked lower than
86% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.03 vs. PFE: 225.46 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 225.46
185.33
344.63
Days Sales Outstanding 61.70
PFE's Days Sales Outstanding is ranked higher than
63% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. PFE: 61.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 61.7
56.83
106.89
Days Payable 103.66
PFE's Days Payable is ranked higher than
71% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.27 vs. PFE: 103.66 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 103.66
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.64
PFE's Dividend Yield % is ranked higher than
89% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. PFE: 3.64 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.69 Max: 10.4
Current: 3.64
2.9
10.4
Dividend Payout Ratio 1.03
PFE's Dividend Payout Ratio is ranked lower than
76% of the 404 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. PFE: 1.03 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 1.03
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked higher than
53% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.78
PFE's Forward Dividend Yield % is ranked higher than
91% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. PFE: 3.78 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.45
PFE's 5-Year Yield-on-Cost % is ranked higher than
88% of the 808 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. PFE: 5.45 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.52 Max: 15.57
Current: 5.45
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.1 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.11
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. PFE: 1.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.45 Max: 9.98
Current: 1.11
0.53
9.98
Price-to-Median-PS-Value 1.10
PFE's Price-to-Median-PS-Value is ranked higher than
52% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. PFE: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.05 Max: 3.28
Current: 1.1
0.43
3.28
Earnings Yield (Greenblatt) % 4.26
PFE's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. PFE: 4.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 4.26
3.5
14.9
Forward Rate of Return (Yacktman) % 2.55
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.09 vs. PFE: 2.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12.5 Max: 23.3
Current: 2.55
2.5
23.3

More Statistics

Revenue (TTM) (Mil) $52,599.00
EPS (TTM) $ 1.19
Beta1.06
Short Percentage of Float0.77%
52-Week Range $29.83 - 37.39
Shares Outstanding (Mil)5,967.84

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,870 53,942 53,367
EPS ($) 2.54 2.73 2.80
EPS without NRI ($) 2.54 2.73 2.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.01%
Dividends per Share ($) 1.28 1.36 1.45
» More Articles for PFE

Headlines

Articles On GuruFocus.com
MainStay Suites in Sidney, Montana, Wins Hotel of the Year Award Jun 22 2017 
Weibo Announces Receipt of a SAPPRFT Notice Jun 22 2017 
AT&T Hosts Cybersecurity Training Camps for Teens Jun 22 2017 
WEIBO (WB) ALERT: J&W Commences an Investigation of Weibo Corporation; Investors Encouraged to Conta Jun 22 2017 
FTSE Russell to Ring The Nasdaq Stock Market Closing Bell Jun 22 2017 
Statement of Clarification with Regards to Tiger Reef, Inc. Letter of Intent Jun 22 2017 
Proteon Therapeutics Announces $22.0 Million Private Placement Jun 22 2017 
Intercept’s Ocaliva® (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award i Jun 22 2017 
Onvia Announces Nationwide Tour to Help Businesses Grow Their Public Sector Sales Jun 22 2017 
Dr Pepper Snapple Group Names Lain Hancock CEO Of Bai Brands Jun 22 2017 

More From Other Websites
Pfizer Inc. – Value Analysis (NYSE:PFE) : June 22, 2017 Jun 22 2017
Pfizer Declares 32-Cent Third-Quarter 2017 Dividend Jun 22 2017
Here's Why Sangamo Therapeutics Rose as Much as 11.7% Today Jun 22 2017
3 Big Stock Charts for Thursday: Pfizer Inc. (PFE), Wal-Mart Stores Inc (WMT) and Costco Wholesale... Jun 22 2017
10 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer Jun 22 2017
Will Pfizer Reexamine a Sale of its Consumer Division? Jun 21 2017
Dems Roast Trump for Leaving Medicare Out of Drug Price Order Jun 21 2017
Pfizer: Time to Sell the Consumer Biz? Jun 21 2017
Pfizer Firing on All Cylinders Jun 21 2017
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 Jun 21 2017
3 Stocks to Watch on Wednesday: Carmax, Inc (KMX), Adobe Systems Incorporated (ADBE) and Sangamo... Jun 21 2017
Is Ford Motor Company (F) Stock Undervalued, Or Cheap for a Reason? Jun 20 2017
Today's iQ100 leaders Jun 20 2017
Pfizer Invites Public To View And Listen To Webcast Of August 1 Conference Call With Analysts Jun 20 2017
Worldwide drug sale forecasts fall as pricing pressures mount Jun 20 2017
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup Jun 20 2017
Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : June 20, 2017 Jun 20 2017
Regeneron’s Praluent May See Gradual Increase in 2017 Demand Jun 20 2017
Better Buy: Pfizer Inc. vs. AbbVie Inc. Jun 20 2017
Top 10 Holdings of Our Ultimate Stock-Pickers' Index Jun 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}